3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
3
Multiple Myeloma
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Solid Tumor
2
Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Refractory or Relapsed Solid Tumors
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms, Plasma Cell
1
Malignant Solid Tumour
1
Lymphangioleiomyomatosis
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Gastrointestinal Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bone Metastases
1
Adult Solid Neoplasm
1
Interventions
Oxaliplatin
31
Fluorouracil
31
Leucovorin
29
Irinotecan
23
Cetuximab
20
Bevacizumab
16
Capecitabine
13
Gemcitabine
11
pembrolizumab
8
Folfox protocol
7
Cisplatin
7
Carboplatin
7
Paclitaxel
6
Nivolumab
6
Cyclophosphamide
6
trifluridine tipiracil drug combination
5
cediranib
5
Erlotinib Hydrochloride
5
adagrasib
4
Ipilimumab
4
IFL protocol
4
Floxuridine
4
Bortezomib
4
veliparib
3
trametinib
3
sargramostim
3
poly ICLC
3
binimetinib
3
Trifluridine
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Colonic Neoplasms
×
Hydroxychloroquine
×
Clear all
NCT04873895
2024-04-26
TACE-Ax-HCQ
Abramson Cancer Center at Penn Medicine
Phase 1
Terminated
5 enrolled